Barrow Robert's Form 4 filing
Definium Therapeutics, Inc. (DFTX) · filed May 17, 2022
- Accession no.
- 0001209191-22-029901
- Filed
- May 17, 2022
- Trade date
- May 15, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001209191-22-030499 (May 19, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Barrow RobertCIK 0001897557 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2022 | Subordinate Voting Shares | FTax withholdingDisposed | −18,948 | $0.82F2 | −$15,537.36 | 3,995,309 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The closing price of our Subordinate Voting Shares as of May 13, 2022 on the NEO was $1.00 Canadian Dollars. This represents the price in United States Dollars.
Referenced by the price of 1 transaction in Table I.